Olivier Tredan, MD, PhD, on Advanced Refractory Cancer and Molecular Screening

2017 ASCO Annual Meeting
Tweet this page

Olivier Tredan, MD, PhD, of the Centre Léon Bérard, discusses results from ProfilER, a study that explored the use of cancer cell genomic alterations to guide treatment in patients with advanced refractory cancer. (Abstract LBA100)

Advertisement

Advertisement



Advertisement